Ignite Creation Date:
2024-05-06 @ 9:20 AM
Last Modification Date:
2024-10-26 @ 12:13 PM
Study NCT ID:
NCT02958384
Status:
UNKNOWN
Last Update Posted:
2018-01-23
First Post:
2016-11-06
Brief Title:
A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies
Sponsor:
Southwest Hospital China
Organization:
Southwest Hospital China
Study Overview
Official Title:
A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies
Status:
UNKNOWN
Status Verified Date:
2018-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The overall purpose of this study is to explore the therapeutic effect of LeY-targeted chimeric antigen receptor TCAR-T cells in the treatment of myeloid malignancies
Detailed Description:
Lewis -YLeY is a difucosylated carbohydrate antigen and although its function is not known it is expressed on a wide range of malignancies including myeloid malignancies LeY-targeted CAR-T in myeloid malignancies had been explored and showed good efficiency in the treatment of myeloid malignancies This trial is designed and conducted to test the safety and effectiveness of LeY-targeted CAR-T
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None